Clinical trial NCT05270200: Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
Official title: To Evaluate Safety and Efficiency of AZA Combined With Chidamide as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation：A Multicenter, Single-arm Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Leukemia, Myeloid, Acute
Keywords: Acute myelogenous leukemia
Allogenetic stem cell transplant
Maintenance therapy
Azacitidine
Chidamide
High-risk AML
Lead sponsor: Zhujiang Hospital
Sponsor class: OTHER
First posted: 2022-03-08
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant. The safety of this combination will also be studied.

Detailed description: The Study Drug:

Azacitidine is designed to block certain genes in cancer cells whose job is to stop the function of the tumor-fighting genes. By blocking the "bad" genes, the tumor-fighting genes may be able to work better.

Chidamide exhibits potent inhibitory effect on cell viability of MDS and AML cells, and the possible mechanism may lie in the downregulation of JAK2/STAT3 signaling through SOCS3 upregulation.

Study Group： If you are found to be eligible to take part in this study,you will receive azacitidine and chidamide.

Study Drug Administration:

You will recieve six courses of azacitidine through a needle under your skin on Days 1-5.Each course is 28 days long.At the same time you will recieve oral chidamide per day for no more than 2 years.

The treatment will start after 60 days post-transplantation and your neutrophil count is of 1.5 × 10⁹ cells per L or higher and non-transfused platelets is of 80 × 10⁹ per L or higher.

The treatment would stop if neutrophil count is less than 0.5 × 10⁹ cells per L or platelets is less than 20 × 10⁹ per L.And it would also stop when grade 3/4 non-hematological adverse events happened.

Study Visit:

You may come back for study visits every month in a year when the treatment start.

Blood and urine will be drawn for routine tests every month. At 1,2,3,4,5,6,9 and 12 months,You will have a bone marrow aspiration to check the status of the disease.

You will have a electrocardiiogram test every 3 months to check the heart function.

Length of Study:

You will be on study treatment for up to 1 year.You will be taken off study early if you experience intolerable side effects or the disease gets worse.

End-of-Treatment Visit:

If you complete the planned treatment with azacitidine and chidamide, you will have an end-of-treatment visit:

Blood and urine will be drawn for routine tests. You will have a bone marrow aspiration to check the status of the disease. You will have a electrocardiiogram test every 3 months to check the heart function.

This is an investigational study. Azacitidine and chidamide are FDA approved and are commercially available for the treatment of acute leukemia.

Eligibility criteria: Inclusion Criteria:

* 1.Age 18 to 60 years old,both male and female
* 2.Be able to understand and sign informed consent
* 3.Patients with a diagnosis of AML not M3 according to the 2016 World Health Organization (WHO) Acute Myeloid Leukemia Classification and Diagnostic
* 4.Patients have AML with poor genetic abnormalities,primary refractory AML,relapsed AML or secondary AML
* 5.Patients with an ECOG performance status 0,1,2 or 3
* 6.Expected survival time ≥ 3 months
* 7.Non-hematological toxicity related to transplantation does not exceed Grade 2
* 8.Laboratory indicators meet the following standards:

  1. 7 days before the first day of the first course of treatment, bilirubin, ALT and AST were all less than 3 times the upper limit of normal.
  2. Measure twice within 7 days before the first day of the first course of treatment, at least 2 days apart, the neutrophil count are greater than 1.5×10/L and without G-CSF treatment.
  3. Measure twice within 7 days before the first day of the first course of treatment, at least 2 days apart, platelet count greater than 80×10/L and without platelet transfusion.
  4. Serum creatinine clearance rate is greater than 30ml/min.

Exclusion Criteria:

* 1.Uncontrollable active infection
* 2.Patients with active hepatitis B or C or HIV infection before enrollment
* 3.Have a grade III-IV graft-versus-host disease

Primary outcomes:
measure: Number of Paticipants With Adverse Events as a Measure of Safety
timeFrame: From the day of stem cell transplantation to one year after stem cell transplantation
measure: One year cumulative incidence of relapse
timeFrame: From the day of stem cell transplantation to one year after stem cell transplantation
Secondary outcomes:
measure: Relapes-free Survival（RFS）
timeFrame: From the day of stem cell transplantation to one year after stem cell transplantation
measure: Overall survival（OS）
timeFrame: From the day of stem cell transplantation to one year after stem cell transplantation
measure: The cumulative Incidence rate of GVHD
timeFrame: From the day of stem cell transplantation to one year after stem cell transplantation
Other outcomes:
Locations:
city: Guanzhou
country: China
facility: Nanfang Hospital of Southern Medical University
state: Guandong
Study officials:
affiliation: Zhujiang Hospital
name: Rui Huang, Doctor
role: PRINCIPAL_INVESTIGATOR
References: